Cartesian Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
38
- Stock Symbol
-
RNAC
- Investments
-
1
- Share Price
-
$24.52
- (As of Friday Closing)
Cartesian Therapeutics General Information
Description
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
Contact Information
Website
www.cartesiantherapeutics.comCorporate Office
- 704 Quince Orchard Road
- Gaithersburg, MD 20878
- United States
Corporate Office
- 704 Quince Orchard Road
- Gaithersburg, MD 20878
- United States
Cartesian Therapeutics Timeline
Cartesian Therapeutics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $24.52 | $22.82 | $11.66 - $42.60 | $586M | 23.9M | 122K | -$47.38 |
Cartesian Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 387,710 | 42,511 | 64,635 | 276,927 |
| Revenue | 54,102 | 26,004 | 110,777 | 85,077 |
| EBITDA | (246,535) | (235,034) | 39,088 | (5,625) |
| Net Income | (229,648) | (219,710) | 35,379 | (25,687) |
| Total Assets | 347,738 | 305,050 | 165,886 | 159,883 |
| Total Debt | 14,867 | 10,955 | 37,925 | 35,281 |
Cartesian Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cartesian Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Cartesian Therapeutics Comparisons
Industry
Financing
Details
Cartesian Therapeutics Competitors (11)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| IM Therapeutics | Venture Capital-Backed | Woburn, MA | ||||
| Locanabio | Venture Capital-Backed | San Diego, CA | ||||
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | ||||
| Intensity Therapeutics | Formerly PE-Backed | Westport, CT | ||||
| AnTolRx | Venture Capital-Backed | Cambridge, MA |
Cartesian Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cartesian Therapeutics Patents
Cartesian Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240148841-A1 | Compositions and methods related to immunoglobulin proteases and fusions thereof | Pending | 11-Aug-2022 | ||
| US-20230381277-A1 | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance | Pending | 08-Apr-2022 | ||
| US-20230372535-A1 | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents | Pending | 25-Mar-2022 | ||
| US-20230357437-A1 | Immunosuppressants in combination with anti-igm agents and related dosing | Pending | 09-Mar-2022 | ||
| US-20230322884-A1 | Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing | Pending | 09-Mar-2022 | C07K14/55 |
Cartesian Therapeutics Executive Team (19)
| Name | Title | Board Seat |
|---|---|---|
| Carsten Brunn | Chief Executive Officer & Board Member | |
| Metin Kurtoglu Ph.D | Chief Technology Officer | |
| Jessica Keliher | Chief People Officer | |
| Christopher Jewell | Chief Scientific Officer | |
| John LaMattina Ph.D | Senior Advisor |
Cartesian Therapeutics Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Carrie Cox | Self | Chairman & Board Member | |
| Carsten Brunn | Cartesian Therapeutics | Chief Executive Officer & Board Member | |
| Michael Singer Ph.D | Self | Board Member | |
| Murat Kalayoglu Ph.D | Self | Board Member | |
| Nishan de Silva MD | Selecta Biosciences | Board Member |
Cartesian Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cartesian Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cartesian Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Selecta Biosciences | 13-Nov-2023 | Drug Discovery |
Cartesian Therapeutics Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Selecta Biosciences | Drug Discovery | Watertown, MA |
Cartesian Therapeutics ESG
Risk Overview
Risk Rating
Updated February, 22, 2024
28.91 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,009
Rank
Percentile
Pharmaceuticals
Industry
of 909
Rank
Percentile
Biotechnology
Subindustry
of 404
Rank
Percentile
Cartesian Therapeutics FAQs
-
When was Cartesian Therapeutics founded?
Cartesian Therapeutics was founded in 2016.
-
Who is the CEO of Cartesian Therapeutics?
Carsten Brunn is the CEO of Cartesian Therapeutics.
-
Where is Cartesian Therapeutics headquartered?
Cartesian Therapeutics is headquartered in Gaithersburg, MD.
-
What is the size of Cartesian Therapeutics?
Cartesian Therapeutics has 38 total employees.
-
What industry is Cartesian Therapeutics in?
Cartesian Therapeutics’s primary industry is Drug Discovery.
-
Is Cartesian Therapeutics a private or public company?
Cartesian Therapeutics is a Public company.
-
What is Cartesian Therapeutics’s stock symbol?
The ticker symbol for Cartesian Therapeutics is RNAC.
-
What is the current stock price of Cartesian Therapeutics?
As of 04-Oct-2024 the stock price of Cartesian Therapeutics is $24.52.
-
What is the current market cap of Cartesian Therapeutics?
The current market capitalization of Cartesian Therapeutics is $586M.
-
What is Cartesian Therapeutics’s current revenue?
The trailing twelve month revenue for Cartesian Therapeutics is $54.1M.
-
Who are Cartesian Therapeutics’s competitors?
IM Therapeutics, Locanabio, Vedanta Biosciences, Intensity Therapeutics, and AnTolRx are some of the 11 competitors of Cartesian Therapeutics.
-
What is Cartesian Therapeutics’s annual earnings per share (EPS)?
Cartesian Therapeutics’s EPS for 12 months was -$47.38.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
